The US market says otherwise @imback.
Those are serious analysts who are unpacking the data and they've got more money and clout than you.
- Forums
- ASX - By Stock
- MSB
- Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
MSB
mesoblast limited
Add to My Watchlist
2.17%
!
$2.35

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-502
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.35 |
Change
0.050(2.17%) |
Mkt cap ! $3.007B |
Open | High | Low | Value | Volume |
$2.29 | $2.39 | $2.27 | $9.283M | 3.962M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 275 | $2.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.38 | 5902 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 275 | 2.350 |
4 | 1264 | 2.340 |
3 | 43464 | 2.330 |
1 | 250 | 2.320 |
2 | 31642 | 2.310 |
Price($) | Vol. | No. |
---|---|---|
2.380 | 5902 | 1 |
2.390 | 34911 | 6 |
2.400 | 98493 | 12 |
2.410 | 15496 | 9 |
2.420 | 2500 | 1 |
Last trade - 16.14pm 18/09/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |